Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 16, Number 2—February 2010

Research

Tropheryma whipplei in Patients with Pneumonia

Sabri Bousbia, Laurent Papazian, Jean-Pierre Auffray, Florence Fenollar, Claude Martin, Wenjun Li, Laurent Chiche, Bernard La Scola, and Didier RaoultComments to Author 
Author affiliations: CNRS-IRD Faculté de Médecine, Marseille, France (S. Bousbia, L. Papazian, F. Fenollar, W. Li, B. La Scola, D. Raoult); Hôpitaux Sud, Marseille (L. Papazian, J.P. Auffray, L. Chiche); Hôpital Nord, Marseille (C. Martin)

Main Article

Table 2

Demographic and clinical data on 6 intensive care unit patients with pneumonia from whom bronchoalveolar lavage samples positive for Tropheryma whipplei DNA were collected, Marseille, France, February 2007–January 2008*

Specimen no. Patient age, y/sex Immunocompromised Diagnosis Type of pneumonia Duration of MV, d Duration of ICU stay, d T. whipplei genotype Outcome
5 39/M Yes (chemotherapy) Septic shock CAP 7 10 New Survived
10 46/M Yes (splenectomy) Coma Aspiration 3 5 3 Survived
82 65/M No Coma Aspiration 16 27 New Survived
86 74/M No Pulmonary embolism VAP 42 42 New Died
183 43/M No Pancreatitis VAP 14 16 New Survived
209 74/M Yes (corticosteroids) Spinal cord injury Aspiration 81 81 ND Died

*MV, mechanical ventilation; ICU, intensive care unit; CAP, community-acquired pneumonia; VAP, ventilator-associated pneumonia; ND, not determined.
†Based on 4 highly variable genomic sequences.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO